You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 44 No. 9, September 1987 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Quantitative Sensory Testing Demonstrates That Subclinical Sensory Neuropathy Is Prevalent in Patients With Cancer

Richard B. Lipton, MD; Bradley S. Galer; Janice P. Dutcher, MD; Russell K. Portenoy, MD; Alan Berger, MD; Joseph C. Arezzo, PhD; Mark Mizruchi, PhD; Peter H. Wiernik, MD; Herbert H. Schaumburg, MD

Arch Neurol. 1987;44(9):944-946.


Abstract

• Vibration threshold (VT) determinations were used to assess the function of the large nerve-fiber sensory system in 171 patients with cancer and 58 healthy subjects. Significant differences in VT indicate dysfunction of this sensory system in the cancer group. Twelve percent of the cancer patients had elevated VT compared with 1.7% of control subjects. Elevated VT was not associated with risk factors for neuropathy such as diabetes, renal disease, poor nutrition, or treatment with chemotherapy. Although VT elevation was associated with alcoholism and increasing age, these variables accounted for only a small proportion of the variance in VT. These data suggest that VT determinations are a useful method for quantifying sensory abnormalities in cancer patients. Sensory abnormalities occur in a significant proportion of patients with cancer and seem to be related directly to the neoplasm, rather than to known risk factors for neuropathy.



Author Affiliations

From the Departments of Neurology (Drs Lipton, Portenoy, Berger, Arezzo, and Schaumburg, and Mr Galer), Oncology (Drs Dutcher and Wiernik), Neuroscience (Dr Arezzo), and Scientific Computing (Dr Mizruchi), Albert Einstein College of Medicine, New York.


Footnotes

Accepted for publication March 20, 1987.

Reprint requests to Department of Neurology, Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461 (Dr Lipton).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Sensory Testing in Human Immunodeficiency Virus Type 1-Infected Men
Gulevich et al.
Arch Neurol 1992;49:1281-1284.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1987 American Medical Association. All Rights Reserved.